INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-20-1726
Abstract: Cyclin-dependent kinases 4 and 6 (CDK4/6), represent a major therapeutic vulnerability for breast cancer. The kinases are clinically targeted via ATP competitive inhibitors (CDK4/6i); however, drug resistance commonly emerges over time. To understand CDK4/6i resistance,… read more here.
Keywords: ink4 tumor; kinase; cdk6; resistance ... See more keywords